Skip to main content

Lantheus Holdings, Inc. (LNTH)

NASDAQ: LNTH · IEX Real-Time Price · USD
27.08 0.07 (0.26%)
Sep 24, 2021 3:49 PM EDT - Market open
Market Cap1.78B
Revenue (ttm)376.27M
Net Income (ttm)-27.45M
Shares Out67.51M
EPS (ttm)-0.41
PE Ration/a
Forward PE30.12
Dividendn/a
Ex-Dividend Daten/a
Volume188,906
Open26.80
Previous Close27.01
Day's Range26.12 - 27.15
52-Week Range10.52 - 28.74
Beta1.44
AnalystsBuy
Price Target32.00 (+18.2%)
Est. Earnings DateNov 4, 2021

About LNTH

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable T...

IndustryHealth Care Equipment & Supplies
IPO DateJun 25, 2015
CEOMary Heino
Employees595
Stock ExchangeNASDAQ
Ticker SymbolLNTH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for LNTH stock is "Buy." The 12-month stock price forecast is 32.00, which is an increase of 18.17% from the latest price.

Price Target
$32.00
(18.17% upside)
Analyst Consensus: Buy

News

Lantheus and RefleXion Announce Development and Commercialization Collaboration with the Potential to Improve Future ...

NORTH BILLERICA, Mass. and HAYWARD, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) and RefleXion Medical, Inc., today announced a development and commercial...

1 week ago - GlobeNewsWire

Lantheus Announces Presentation at the 2021 American Urological Association (AUA) Annual Meeting

Highlights Piflufolastat F 18's Potential to Change Initial Risk Assessment and Intended Patient Management in High-Risk Prostate Cancer

2 weeks ago - GlobeNewsWire

Lantheus Holdings to Present at Upcoming Investor Conferences

NORTH BILLERICA, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagnost...

3 weeks ago - GlobeNewsWire

Lantheus Announces the First and Only FDA Cleared AI-Enabled PSMA Digital Application, aPROMISE™, Strengthening Lanth...

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced today that its subsidiary, EXINI Diagnostics AB, was granted 510(k) clearance by the U.S. Food and Dr...

1 month ago - Business Wire

Lantheus Stock Gains As Q2 Earnings Surpasses Expectations; Raises FY2021 Outlook

Lantheus Holdings Inc (NASDAQ: LNTH) clocked $101.1 million in sales for Q2 of 2021, beating the consensus of $94.9 million, representing an increase of 53.1% Y/Y. Sales exceeded management's guidance r...

1 month ago - Benzinga

Lantheus Holdings (LNTH) Q2 Earnings and Revenues Beat Estimates

Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 120.00% and 6.83%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Lantheus Holdings: Q2 Earnings Insights

Shares of Lantheus Holdings (NASDAQ:LNTH) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share increased 10.00% over the past year to $0.11, which beat the est...

1 month ago - Benzinga

Lantheus Holdings, Inc. Reports Second Quarter 2021 Financial Results

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics a...

1 month ago - Business Wire

Analysts Estimate Lantheus Holdings (LNTH) to Report a Decline in Earnings: What to Look Out for

Lantheus Holdings (LNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Lantheus Holdings to Host Second Quarter 2021 Earnings Conference Call and Webcast on July 28, 2021 at 8:00 a.m. East...

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 28, 202...

2 months ago - Business Wire

Lantheus To Present Piflufolastat F 18 Data at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) ...

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted...

3 months ago - Business Wire

Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates

The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive outcomes.

Other symbols:APLSBBIOJNJ
3 months ago - Benzinga

Lantheus Holdings (LNTH) Soars 16.8%: Is Further Upside Left in the Stock?

Lantheus Holdings (LNTH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increa...

3 months ago - Zacks Investment Research

Why Lantheus Stock Is Soaring Today

Investors are cheering FDA approval for the company's prostate cancer imaging agent.

3 months ago - The Motley Fool

Lantheus Shares Trading Higher On FDA Approval For Imaging Agent For Identification Of Prostate Cancer

The FDA has approved Lantheus Holdings Inc's (NASDAQ: LNTH) Pylarify, a positron emission tomography (PET) imaging agent, to identify suspected metastasis or recurrence of prostate cancer. Pylarify is a...

3 months ago - Benzinga

Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Avai...

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeut...

3 months ago - Business Wire

Is the Options Market Predicting a Spike in Lantheus Holdings (LNTH) Stock?

Investors need to pay close attention to Lantheus Holdings (LNTH) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

Lantheus Holdings Announces Presentation Featuring 18F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent...

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeut...

4 months ago - Business Wire

Lantheus Holdings to Present at the Jefferies Virtual Healthcare Conference

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics a...

4 months ago - Business Wire

Lantheus Holdings (LNTH) Beats Q1 Earnings and Revenue Estimates

Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 600.00% and 5.54%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Lantheus Holdings: Q1 Earnings Insights

Shares of Lantheus Holdings (NASDAQ:LNTH) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share fell 86.11% over the past year to $0.05, which beat the estimate...

4 months ago - Benzinga

Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics a...

4 months ago - Business Wire

EXINI Diagnostics AB, a Lantheus Company, Receives CE Mark Clearance for aPROMISE in Europe

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--EXINI Diagnostics AB, a subsidiary of Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imagin...

4 months ago - Business Wire

Lantheus Grants Allegheny Health Network Exclusive Rights for the Use of its Microbubbles in Combination with Ultraso...

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics a...

4 months ago - Business Wire

Lantheus Holdings to Host First Quarter 2021 Earnings Conference Call and Webcast on May 4, 2021 at 8:00 a.m. Eastern...

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Tuesday, May 4, 2021, t...

5 months ago - Business Wire